MTFR2
gene geneOn this page
Summary
MTFR2 (mitochondrial fission regulator 2, HGNC:21115) is a protein-coding gene on chromosome 6q23.3, encoding Mitochondrial fission regulator 2 (Q6P444). May play a role in mitochondrial aerobic respiration essentially in the testis.
Predicted to be involved in aerobic respiration and mitochondrial fission. Located in mitochondrion.
Source: NCBI Gene 113115 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 72 total
- MANE Select transcript:
NM_001099286
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:21115 |
| Approved symbol | MTFR2 |
| Name | mitochondrial fission regulator 2 |
| Location | 6q23.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000146410 |
| Ensembl biotype | protein_coding |
| Entrez | 113115 |
Gene structure
Transcript identifiers
Ensembl transcripts: 9 — 6 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron
ENST00000367784, ENST00000418509, ENST00000420702, ENST00000445767, ENST00000451457, ENST00000527338, ENST00000532958, ENST00000919551, ENST00000952723
RefSeq mRNA: 3 — MANE Select: NM_001099286
NM_001099286, NM_001318738, NM_138419
CCDS: CCDS5176
Canonical transcript exons
ENST00000420702 — 8 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001629537 | 136249976 | 136250311 |
| ENSE00003515364 | 136241444 | 136241676 |
| ENSE00003559383 | 136231034 | 136231388 |
| ENSE00003565761 | 136244765 | 136244869 |
| ENSE00003573198 | 136233325 | 136233499 |
| ENSE00003592532 | 136249037 | 136249153 |
| ENSE00003636140 | 136242861 | 136242973 |
| ENSE00003642674 | 136239466 | 136239820 |
Expression profiles
Bgee: expression breadth ubiquitous, 190 present calls, max score 94.87.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.9445 / max 88.6392, expressed in 968 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 75742 | 2.9445 | 968 |
Top tissues by expression
254 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| buccal mucosa cell | CL:0002336 | 94.87 | gold quality |
| secondary oocyte | CL:0000655 | 92.50 | gold quality |
| oocyte | CL:0000023 | 91.61 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 87.44 | gold quality |
| sperm | CL:0000019 | 86.58 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 85.04 | gold quality |
| ventricular zone | UBERON:0003053 | 79.22 | gold quality |
| ileal mucosa | UBERON:0000331 | 77.24 | gold quality |
| right testis | UBERON:0004534 | 76.16 | gold quality |
| testis | UBERON:0000473 | 76.00 | gold quality |
| bone marrow | UBERON:0002371 | 75.96 | gold quality |
| left testis | UBERON:0004533 | 75.48 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 75.11 | gold quality |
| rectum | UBERON:0001052 | 73.43 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 73.21 | gold quality |
| ganglionic eminence | UBERON:0004023 | 73.12 | gold quality |
| vermiform appendix | UBERON:0001154 | 72.81 | gold quality |
| stromal cell of endometrium | CL:0002255 | 71.62 | gold quality |
| tibialis anterior | UBERON:0001385 | 70.46 | gold quality |
| lymph node | UBERON:0000029 | 70.18 | gold quality |
| gingival epithelium | UBERON:0001949 | 70.18 | gold quality |
| esophagus mucosa | UBERON:0002469 | 68.96 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 68.93 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 68.19 | gold quality |
| amniotic fluid | UBERON:0000173 | 67.89 | gold quality |
| thymus | UBERON:0002370 | 67.66 | gold quality |
| granulocyte | CL:0000094 | 67.37 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 67.10 | gold quality |
| pancreatic ductal cell | CL:0002079 | 66.95 | silver quality |
| adult organism | UBERON:0007023 | 66.81 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 4.49 |
Regulation
Is transcription factor: yes
Downstream targets (CollecTRI)
1 targets.
| Target | Regulation |
|---|---|
| TP53 | Unknown |
miRNA regulators (miRDB)
22 targeting MTFR2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3185 | 99.99 | 68.12 | 1959 |
| HSA-MIR-4496 | 99.88 | 68.89 | 2236 |
| HSA-LET-7A-2-3P | 99.87 | 70.53 | 1921 |
| HSA-LET-7G-3P | 99.85 | 70.43 | 1929 |
| HSA-MIR-132-3P | 99.73 | 70.56 | 1424 |
| HSA-MIR-212-3P | 99.73 | 70.65 | 1424 |
| HSA-MIR-33A-3P | 99.70 | 70.27 | 3362 |
| HSA-MIR-4261 | 99.59 | 70.30 | 3415 |
| HSA-MIR-6513-3P | 99.59 | 69.77 | 1102 |
| HSA-MIR-147B-5P | 99.45 | 70.62 | 2432 |
| HSA-MIR-4797-5P | 99.39 | 68.01 | 1354 |
| HSA-MIR-6507-5P | 99.36 | 70.46 | 2524 |
| HSA-MIR-4263 | 99.18 | 69.25 | 2236 |
| HSA-MIR-455-3P | 98.94 | 67.68 | 878 |
| HSA-MIR-6796-3P | 98.68 | 65.49 | 689 |
| HSA-MIR-4773 | 98.35 | 67.30 | 1710 |
| HSA-MIR-12120 | 98.05 | 68.44 | 1768 |
| HSA-MIR-924 | 97.78 | 66.21 | 681 |
| HSA-MIR-376C-3P | 97.63 | 68.88 | 1263 |
| HSA-MIR-592 | 96.59 | 67.59 | 817 |
| HSA-MIR-6806-5P | 96.37 | 68.74 | 587 |
| HSA-MIR-217-3P | 95.67 | 68.42 | 1000 |
Literature-anchored findings (GeneRIF, showing 6)
- Mitochondrial fission regulator 2 (MTFR2) promotes growth, migration, invasion and tumour progression in breast cancer cells. (PMID:31740625)
- Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics. (PMID:34039308)
- Upregulated expression of MTFR2 as a novel biomarker predicts poor prognosis in hepatocellular carcinoma by bioinformatics analysis. (PMID:34156259)
- Transcription factor HOXC10 activates the expression of MTFR2 to regulate the proliferation, invasion and migration of colorectal cancer cells. (PMID:34523692)
- Dysregulation of MTFR2, ATP5IF1 and BAK1 in Sertoli cells relates to idiopathic non-obstructive azoospermia via inhibiting mitochondrial fission and inducing mitochondrial dysfunctiondagger. (PMID:37903059)
- MTFR2-dependent mitochondrial fission promotes HCC progression. (PMID:38238834)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | mtfr2 | ENSDARG00000060394 |
| mus_musculus | Mtfr2 | ENSMUSG00000019992 |
| rattus_norvegicus | ENSRNOG00000078862 |
Paralogs (2): MTFR1 (ENSG00000066855), MTFR1L (ENSG00000117640)
Protein
Protein identifiers
Mitochondrial fission regulator 2 — Q6P444 (reviewed: Q6P444)
Alternative names: DUF729 domain-containing protein 1
All UniProt accessions (3): Q6P444, E9PN39, H0YEA6
UniProt curated annotations — full annotation on UniProt →
Function. May play a role in mitochondrial aerobic respiration essentially in the testis. Can also promote mitochondrial fission.
Subcellular location. Mitochondrion.
Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.
Similarity. Belongs to the MTFR1 family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q6P444-1 | 1 | yes |
| Q6P444-2 | 2 |
RefSeq proteins (3): NP_001092756, NP_001305667, NP_612428 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR007972 | Mtfr1 | Family |
Pfam: PF05308
UniProt features (13 total): modified residue 4, compositionally biased region 3, splice variant 2, region of interest 2, initiator methionine 1, chain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q6P444-F1 | 62.11 | 0.11 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (4): 328, 2, 119, 291
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 158 (showing top):
RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_ORGANELLE_FISSION, MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_MITOCHONDRIAL_FISSION, DODD_NASOPHARYNGEAL_CARCINOMA_UP, FISCHER_DREAM_TARGETS, TURASHVILI_BREAST_CARCINOMA_DUCTAL_VS_LOBULAR_UP, GOBP_CELLULAR_RESPIRATION, NUYTTEN_EZH2_TARGETS_DN, MARSON_BOUND_BY_E2F4_UNSTIMULATED
GO Biological Process (3): mitochondrial fission (GO:0000266), mitochondrion organization (GO:0007005), aerobic respiration (GO:0009060)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (1): mitochondrion (GO:0005739)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| mitochondrion organization | 1 |
| organelle fission | 1 |
| organelle organization | 1 |
| cellular respiration | 1 |
| binding | 1 |
| cytoplasm | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
1166 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| MTFR2 | DERL1 | Q9BUN8 | 431 |
| MTFR2 | KRTAP19-7 | Q3SYF9 | 431 |
| MTFR2 | C4orf46 | Q504U0 | 374 |
| MTFR2 | OR6X1 | Q8NH79 | 370 |
| MTFR2 | OR13J1 | Q8NGT2 | 366 |
| MTFR2 | ZNF565 | Q8N9K5 | 359 |
| MTFR2 | SHCBP1 | Q8NEM2 | 348 |
| MTFR2 | TTK | P33981 | 338 |
| MTFR2 | FAM181A | Q8N9Y4 | 305 |
| MTFR2 | CENPN | Q96H22 | 304 |
| MTFR2 | ZNF781 | Q8N8C0 | 303 |
| MTFR2 | POTEM | A6NI47 | 303 |
| MTFR2 | FAM72B | Q86X60 | 274 |
| MTFR2 | TTC14 | Q96N46 | 271 |
| MTFR2 | ZNF791 | Q3KP31 | 269 |
| MTFR2 | PHETA1 | Q8N4B1 | 269 |
IntAct
53 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| CFTR | ESYT2 | psi-mi:“MI:2364”(proximity) | 0.710 |
| ALAS1 | MTFR2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MTFR2 | ALAS1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MTFR2 | TRIM23 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GOLGA2 | MTFR2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAGEA12 | MTFR2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TFIP11 | MTFR2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TRIM23 | MTFR2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MTFR2 | GOLGA2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MTFR2 | TFIP11 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MTFR2 | MAGEA12 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SLC2A12 | METTL15 | psi-mi:“MI:0914”(association) | 0.530 |
| NPY2R | RTL8C | psi-mi:“MI:0914”(association) | 0.530 |
| SCNN1D | ABHD16A | psi-mi:“MI:0914”(association) | 0.530 |
| ATG14 | CETN2 | psi-mi:“MI:0914”(association) | 0.530 |
| MTFR2 | CFTR | psi-mi:“MI:0915”(physical association) | 0.520 |
| HTRA2 | HAX1 | psi-mi:“MI:2364”(proximity) | 0.420 |
| MTFR2 | SIRT1 | psi-mi:“MI:0915”(physical association) | 0.400 |
| MTFR2 | KLHDC2 | psi-mi:“MI:0915”(physical association) | 0.400 |
| MTFR2 | SPTB | psi-mi:“MI:0915”(physical association) | 0.400 |
| PB2 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (66): MTFR2 (Two-hybrid), MTFR2 (Two-hybrid), MTFR2 (Two-hybrid), MTFR2 (Two-hybrid), MTFR2 (Two-hybrid), KLHDC2 (Affinity Capture-MS), MTFR2 (Affinity Capture-MS), MTFR2 (Affinity Capture-MS), MTFR2 (Affinity Capture-MS), MTFR2 (Affinity Capture-MS), MTFR2 (Affinity Capture-MS), SIRT1 (Affinity Capture-MS), MTFR2 (Affinity Capture-MS), MTFR2 (Affinity Capture-MS), MTFR2 (Affinity Capture-MS)
ESM2 similar proteins: A2AIW0, A2YX04, A5WUN7, A8MWX3, B0K035, B2GUZ2, D3IUT5, D4A4D7, F1RCE7, G3V9A7, Q08BD8, Q0VFP3, Q3ZBW7, Q4R707, Q4V7T5, Q52KF3, Q58CR1, Q5R3Z9, Q5T5Y3, Q5XII9, Q640U0, Q641E3, Q6AWX6, Q6DF94, Q6GP48, Q6IRN6, Q6NPP4, Q6P444, Q6S7F2, Q6Z8M8, Q700C2, Q75LH6, Q7T3E8, Q7YR76, Q8BHE0, Q8C263, Q8GSA7, Q8IZQ8, Q8K298, Q8RY95
Diamond homologs: B0K035, F1RCE7, G3V9A7, Q08BD8, Q0VFP3, Q3ZBW7, Q4V7T5, Q58CR1, Q5R3Z9, Q5RFN3, Q5XII9, Q6GP48, Q6P444, Q7T3E8, Q8VED8, Q99MB2, Q9CWE0, Q9H019, Q15390, Q9PTD5
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
72 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 57 |
| Likely benign | 5 |
| Benign | 1 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1050 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:136231384:CCAAA:C | acceptor_gain | 1.0000 |
| 6:136231385:CAAA:C | acceptor_gain | 1.0000 |
| 6:136231385:CAAAC:C | acceptor_gain | 1.0000 |
| 6:136231388:ACTG:A | acceptor_loss | 1.0000 |
| 6:136231389:C:CC | acceptor_gain | 1.0000 |
| 6:136233319:GCTTA:G | donor_loss | 1.0000 |
| 6:136233320:CTTA:C | donor_loss | 1.0000 |
| 6:136233322:T:TG | donor_loss | 1.0000 |
| 6:136233323:A:AC | donor_gain | 1.0000 |
| 6:136233323:AC:A | donor_gain | 1.0000 |
| 6:136233324:C:CC | donor_gain | 1.0000 |
| 6:136233324:C:CT | donor_loss | 1.0000 |
| 6:136233324:CC:C | donor_gain | 1.0000 |
| 6:136241440:TTA:T | donor_loss | 1.0000 |
| 6:136241441:TAC:T | donor_loss | 1.0000 |
| 6:136241442:A:AC | donor_gain | 1.0000 |
| 6:136241442:ACTAG:A | donor_loss | 1.0000 |
| 6:136241443:C:A | donor_loss | 1.0000 |
| 6:136241443:C:CA | donor_gain | 1.0000 |
| 6:136241443:CT:C | donor_gain | 1.0000 |
| 6:136241443:CTA:C | donor_gain | 1.0000 |
| 6:136241443:CTAG:C | donor_gain | 1.0000 |
| 6:136241443:CTAGA:C | donor_gain | 1.0000 |
| 6:136241467:T:A | donor_gain | 1.0000 |
| 6:136241672:TATTT:T | acceptor_gain | 1.0000 |
| 6:136241673:ATTT:A | acceptor_gain | 1.0000 |
| 6:136241674:TTT:T | acceptor_gain | 1.0000 |
| 6:136241675:TT:T | acceptor_gain | 1.0000 |
| 6:136241677:C:CC | acceptor_gain | 1.0000 |
| 6:136241678:T:C | acceptor_loss | 1.0000 |
AlphaMissense
2537 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 6:136244825:A:C | S36R | 0.988 |
| 6:136244825:A:T | S36R | 0.988 |
| 6:136244827:T:G | S36R | 0.988 |
| 6:136241512:A:G | L149P | 0.987 |
| 6:136244820:A:T | V38D | 0.980 |
| 6:136241503:A:G | L152P | 0.976 |
| 6:136233406:A:C | F321L | 0.975 |
| 6:136233406:A:T | F321L | 0.975 |
| 6:136233408:A:G | F321L | 0.975 |
| 6:136233419:A:T | L317H | 0.975 |
| 6:136244817:C:G | R39P | 0.975 |
| 6:136233340:A:C | S343R | 0.970 |
| 6:136233340:A:T | S343R | 0.970 |
| 6:136233342:T:G | S343R | 0.970 |
| 6:136233419:A:G | L317P | 0.970 |
| 6:136244818:G:T | R39S | 0.969 |
| 6:136233423:C:G | A316P | 0.967 |
| 6:136241489:C:G | A157P | 0.966 |
| 6:136239505:A:G | L277P | 0.964 |
| 6:136241494:T:G | Q155P | 0.963 |
| 6:136241524:A:G | L145P | 0.958 |
| 6:136233431:A:T | I313K | 0.957 |
| 6:136241500:C:G | R153P | 0.952 |
| 6:136244777:T:A | R52S | 0.950 |
| 6:136244777:T:G | R52S | 0.950 |
| 6:136244808:C:T | G42E | 0.946 |
| 6:136244826:C:A | S36I | 0.943 |
| 6:136233431:A:G | I313T | 0.942 |
| 6:136244828:C:A | R35S | 0.942 |
| 6:136244828:C:G | R35S | 0.942 |
dbSNP variants (sampled 300 via entrez): RS1000303532 (6:136236006 C>T), RS1000494300 (6:136247485 T>C), RS1000895421 (6:136251735 A>G), RS1001083912 (6:136248045 C>G), RS1001110114 (6:136246069 C>A,T), RS1001536579 (6:136247564 T>C), RS1001545979 (6:136243197 C>A,T), RS1001581877 (6:136246924 A>G), RS1001632248 (6:136240918 CG>C), RS1001717004 (6:136232403 T>C), RS1001819076 (6:136235642 A>C), RS1001834395 (6:136249351 T>C), RS1001884750 (6:136244542 C>T), RS1002057356 (6:136233769 T>C), RS1002469940 (6:136245258 T>A,G)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST009391_790 | Metabolite levels | 2.000000e-06 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0010395 | sphingomyelin 22:0 measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
57 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Cyclosporine | decreases expression | 3 |
| sodium arsenite | increases expression, decreases expression | 2 |
| (+)-JQ1 compound | decreases expression, increases expression | 2 |
| Valproic Acid | decreases methylation, increases expression | 2 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide | decreases expression | 1 |
| afuresertib | decreases expression | 1 |
| FR900359 | decreases phosphorylation | 1 |
| TAK-243 | increases sumoylation | 1 |
| dicrotophos | decreases expression | 1 |
| bisphenol A | decreases expression | 1 |
| arsenite | affects binding, increases reaction | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| zinc chromate | decreases expression, increases abundance | 1 |
| isobutyl alcohol | affects cotreatment, decreases expression, increases abundance | 1 |
| chromium hexavalent ion | decreases expression, increases abundance | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| perfluoro-n-nonanoic acid | decreases expression | 1 |
| K 7174 | decreases expression | 1 |
| teriflunomide | decreases expression | 1 |
| jinfukang | increases expression | 1 |
| incobotulinumtoxinA | decreases expression | 1 |
| theaflavin-3,3’-digallate | affects expression | 1 |
| Dasatinib | decreases expression | 1 |
| Resveratrol | affects cotreatment, increases expression | 1 |
| Temozolomide | increases expression | 1 |
| Vorinostat | increases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Air Pollutants | affects expression, increases abundance | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.